The Angelini family built most of its wealth in Italy over a hundred years. Now the fourth generation is making a major bet that the next part of the story will unfold in the United States. Angelini Industries is linked to a family group thought to be worth around $10 billion. The wider business brought in about $2.5 billion in revenue.
For years, the pharmaceutical work was strongest in Europe. Its products have included well-known medicines used for depression and epilepsy. Still, the family has started to treat the U.S. as hard to overlook. In May 2026, Angelini Pharma agreed to buy Catalyst Pharmaceuticals, a U.S. company.
The price was about $4.1 billion in cash. The plan was to give the Italian firm a clear sales and marketing footprint in the biggest drug market. It was also meant to grow its reach in rare diseases. The purchase was finalized in July 2026. For a family company that once took a careful, slow approach, this is a sharp shift in direction.
A Family Business That Started With A Pharmacist
In 1919, Francesco Angelini, aged 32 and a pharmacist, started a small shop in Ancona, Italy. He made and sold medicines there. Over a hundred years went by. During that time, the company grew into a broader business group . Today, Angelini Industries is not limited to pharma. It is involved in consumer goods, wineries, and robotics too.
Even with that wider reach, health care still drives the main plan for growth. Angelini Pharma is the biggest part of the group. For many years, it leaned on medicines that already had strong places in European markets. Tachipirina is one of its best-known products. It is an acetaminophen-based medicine, and it became a common name in Italy. The company also created trazodone, an antidepressant that is still used a lot.
For decades, this approach brought steady results and money. Then the fourth generation started to push for something larger and more daring.
The Fourth Generation Wanted To Rekindle Innovation
Thea Paola Angelini took control of the family business in the fourth generation. Her husband, Sergio Marullo di Condojanni, later became CEO of both Angelini Industries and Angelini Pharma. They were not trying to keep things as they were. They wanted a clearer change in direction. Angelini needed to be seen again as a company that drives innovation.
So they pushed toward newer treatments. This focus was strong in brain health and rare diseases. The plan did not start with the Catalyst deal. It had already been underway earlier.
In 2021, Angelini Pharma bought the Swiss firm Arvelle Therapeutics. The price could reach $960 million. The goal was to secure European rights to an epilepsy therapy.
Then, in 2025, Angelini Pharma bought non-U.S. rights to another rare epilepsy drug. This came from Grin Therapeutics. The deal could be worth up to $570 million. Around the same time, the company set up a venture fund. It was backed by about $350 million for life-sciences startups. Taken together, these steps helped set up the bigger move in America.
Why The U.S. Market Was So Important
The US drug market has a feature that is hard to copy: it runs on a massive scale. Here you find very large drug makers. You also get deep funding for healthcare. And there are major biotech clusters.
Still, moving into this space from Europe is not straightforward. A firm has to know how US regulators work. It needs a sales and operations setup. It must build ties with doctors and health systems. It also needs a path into new drug programs.
Angelini thought an acquisition might shorten the timeline. Buying a US company, they believed, could bring the needed footing sooner. Catalyst Pharmaceuticals fit that plan.
The $4.1 Billion Catalyst Deal
Catalyst works on rare illnesses that are hard to treat. A big part of its work is in nervous system and muscle-related conditions. In the deal terms, Angelini proposed $31.50 for each Catalyst share. The payment would be in cash. This would place the equity value near $4.1 billion. Angelini’s bid came with a 21% premium. The premium was based on Catalyst’s stock price from April 22, 2026, before the news.
Support came from Blackstone funds and Italy’s CDP Equity. BNP Paribas also provided financing help. After the buyout, Angelini Pharma moved up in size right away.
Before the deal, Catalyst had three marketed products. The company expected the deal to bring about $600 million more revenue to Angelini Pharma. That figure was about a 40% rise from the revenue level before the deal. Still, it is a big leap for a firm whose drug business had mostly been tied to Europe.
Rare Diseases Offer A Different Kind Of Opportunity
Catalyst puts a lot of weight on rare diseases in this deal. One of its key drugs is used for Lambert-Eaton myasthenic syndrome. That condition is rare and autoimmune. It can lead to major muscle weakness. Markets for rare diseases look different. There may be fewer possible patients.
But care often needs deep, specific know-how. In some cases, rivals are not as packed as they are in huge disease areas. For Angelini, this is a chance to grow in a focused lane. It can build skills in that niche.
It does not have to jump into every big drug category right away. Catalyst also already works in neurological diseases. So this feels like a planned match, not just a big purchase.
The U.S. Move Is Also About Speed
Family businesses often run into friction when they try to go abroad. Plans usually reflect what earlier owners decided, and those views stick around through the generations. Angelini’s fourth generation seems ready to push ahead sooner. Rather than taking years to grow a U.S. operation from nothing, the family bought an existing business with a large price tag.
That deal helped them show up in the market right away, with a clear commercial base. This path can be harder on the finances. Still, it may cut down the time before the company becomes a serious name in the U.S.
The reasoning is not complicated. If the United States matters for the company’s long-term plan in pharmaceuticals, then waiting ten more years to put infrastructure in place may cost them chances that do not come back.
The Family Is Still Thinking Beyond One Acquisition
The Catalyst deal probably is not the last step. Angelini has put money into life sciences via its venture unit. It has also gone after other opportunities, including work tied to brain health.
Because of that, the family may be aiming for a wider network around medicines. They might not want to bank on a single large buyout.
Over time, this plan could bring together old drugs, later purchases, venture funding, and research links. That mix can give Angelini more than one route to find new treatments and turn them into products. It also helps limit the danger of leaning only on a few older medicines.
The Challenge Of Becoming A Global Pharma Player
Growth in the United States will bring real hurdles. A deal worth $4.1 billion has to pay off in measurable growth, not just promises . Angelini also has to bring Catalyst into the business carefully. The goal is to keep the product lineup and the key relationships that made the U.S. company valuable.
Meanwhile, the pharma market is shifting at a fast pace. Price pressure is rising, and rules are getting stricter. Clinical development is expensive, and bigger firms are pushing harder. Because of that, the family cannot rely on money alone. They will need strong follow-through. The story also highlights how changing market conditions can affect a company’s valuation, especially when investors begin reassessing future growth, competition and long-term risks.
The Bottom Line
Angelini’s push into the United States is a big shift for a firm that for years grew mainly from its base in Italy. The fourth generation says that keeping the family’s drug legacy is not the end of the story. They want more than continuity. They want growth.
Angelini Pharma is paying $4.1 billion for Catalyst, and that deal puts the company in the U.S. right away. It also boosts its work in rare diseases and brain health. Other deals and early-stage bets already made by the company suggest this is not just one purchase. It looks like a plan that has been building for some time.
The company started over a century ago in Ancona, with a pharmacist at the beginning. Now the next step aims higher than before. The focus is no longer limited to staying a strong Italian drug maker. The plan is to turn into a global healthcare company. With so much money now tied to the U.S. market, the family’s main wager has started.
The growing relationship between influence and ownership can also be seen in how celebrities are turning fame into billion-dollar business empires, using their audiences to build brands, investments and long-term assets.
